Nucor earnings beat by $0.08, revenue fell short of estimates
Harvard Bioscience Inc. (NASDAQ:HBIO) stock has reached a 52-week low, trading at $0.56, as the company faces a tumultuous period in the market. According to InvestingPro data, the stock’s RSI indicates oversold conditions, while analysts maintain price targets ranging from $3.00 to $4.50. This latest price level reflects a significant downturn for the stock, which has seen a dramatic 1-year change with a decline of -87.47%. While the company currently operates with a significant debt burden and isn’t profitable over the last twelve months, InvestingPro analysis indicates net income is expected to grow this year, with analysts projecting a return to profitability. Investors are closely monitoring the company’s performance and market conditions, as the stock’s current position marks a critical juncture for Harvard Bioscience’s financial outlook and future growth prospects. Get the full picture with 13 additional key insights available on InvestingPro.
In other recent news, Harvard Bioscience reported its fourth-quarter 2024 earnings, surpassing expectations with an earnings per share (EPS) of $0.06, compared to the forecasted $0.05. The company also exceeded revenue projections, achieving $24.6 million against the anticipated $24.15 million. Despite these positive results, the company experienced a 13% year-over-year decline in quarterly revenue and a 16% drop in full-year revenue compared to 2023, attributed to challenges in academic research funding. Harvard Bioscience is focusing on new product opportunities and cost management to navigate these challenges. The company provided guidance for the first quarter of 2025, expecting revenue between $19 million and $21 million and gross margins in the range of 56-58%. Analyst firm KeyBanc inquired about the company’s debt refinancing efforts, which are expected to be completed by June 2025. Harvard Bioscience is also exploring growth opportunities in CAR T therapy and organoid research, aiming to drive future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.